CDR3 Therapeutics

CDR3 Therapeutics is a private, pre-clinical stage biotech founded in 2019 and based in Cambridge, USA. The company is developing a patented platform that leverages stem cells to engineer durable, self-renewing immune cells designed to provide lasting therapeutic effects against cancers and viral diseases. The website content is minimal and appears outdated (last updated mid-2021), suggesting the company may be in a very early or dormant operational stage, actively seeking investment to advance its technology.

Patented platform using engineered stem cells to create a self-renewing, long-lasting source of gene-targeted immune cells (e.g., T cells) within the body for treating cancers and viral diseases.

Competes in a crowded and well-funded cell therapy space where many companies are working on next-gen approaches to improve persistence, including using stem cells, memory T cell subsets, and universal off-the-shelf platforms. CDR3 shows no visible differentiation or progress compared to public competitors.